Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Bolt Biotherapeutics (BOLT): Evaluating the +138% Move to the $14.50 Target

Bolt Biotherapeutics (BOLT): Evaluating the +138% Move to the $14.50 Target

Key Takeaways

  • The $14.50 target represents the average of the two most recent analyst price targets: $7.00 from H.C. Wainwright (March 2026) and $22.00 from Rodman & Renshaw (May 2026).
  • At the November 13, 2026 closing price of $6.08, reaching $14.50 would require approximately 138% upside.
  • Earlier targets create a wide spectrum, from Lake Street’s $75 (August 2025) to Leerink Partners’ $6 (September 2025).
  • All existing targets predate the October 23, 2026 reverse merger with Prana Therapies.
  • Positive elements include a $120 million PIPE financing, a Phase 2 lead asset in sizable indications, and a refreshed leadership team.
  • Major risks center on significant dilution, persistent operating losses, a market capitalization below $20 million, and binary clinical outcomes.
  • Additional context is available on the stock’s Major News, Today’s Price Move, Forecast, and Earnings sections.

What the Analyst Targets Indicate

Coverage of BOLT remains limited, and every published target was issued before the October 2026 merger. The two most recent figures are a $7.00 Buy rating from H.C. Wainwright’s Robert Burns (reiterated March 13, 2026) and a $22.00 Buy rating from Rodman & Renshaw’s Michael King Jr. (May 28, 2026). Their midpoint of $14.50 serves as the reference point here. Earlier calls, such as Lake Street’s $75 Buy (adjusted post reverse split) and Leerink Partners’ $6 Hold, illustrate the broad dispersion among the few analysts who follow the name. No updates have appeared since the Prana transaction, so these figures reflect the prior pipeline rather than the restructured entity.

Where the Stock Stands Today

BOLT closed at $6.08 on November 13, 2026, inside a 52-week range of $3.10 to $7.78. Achieving the $14.50 level from that price would demand roughly 138% appreciation. The October 2026 deal, which brought in Prana Therapies and raised $120 million gross via a Series D PIPE plus warrants (with potential for another $60 million upon exercise), left legacy shareholders with about 6.9% of the fully diluted equity. Prana holders hold roughly 51.7% and new investors about 41.4%, effectively transferring control.

Elements That Could Support Higher Prices

The reoriented pipeline and improved capital position provide the primary support. Lead candidate PRA-216, an IL-4Rα/TSLP bispecific antibody, is advancing in Phase 2 trials for asthma, COPD, and atopic dermatitis, with a fourth study in eosinophilic esophagitis planned; proof-of-concept data is anticipated in 2027. The acquired INSPIRE platform offers a next-generation multispecific antibody approach. The $120 million financing extends the runway and is intended to cover multiple milestones. I also checked comparable names using Tickeron’s AI Screener to gauge industry context.

Obstacles That Could Limit Upside

Structural and clinical hurdles remain substantial. The company posted a roughly $19.6 million net loss in the third quarter of 2026 with minimal revenue and continues to operate at a loss against a common-share market value well under $20 million. Conversion of Series D preferred stock, a possible reverse split (ratios from 1-for-2 to 1-for-12) for Nasdaq compliance, and potential increases in authorized shares all signal further dilution. Any setback with PRA-216 or delays in the 2027 readouts would undermine the core thesis, while an announced shareholder investigation into merger terms adds governance questions.

Technical Context and Market Dynamics

The 52-week high of $7.78, reached in late October 2026, sits just above current levels and marks the nearest resistance. A sustained break above that area would represent the first concrete step toward $14.50. The September 2026 low of $3.10 serves as the key support zone. With a small float and modest trading volume, price swings can be pronounced in either direction.

Time Horizon and Items Worth Monitoring

Analyst targets generally look out about 12 months, though none postdate the merger. Near-term focus should remain on the 2027 Phase 2 readouts for PRA-216, any further financing or votes on preferred conversion and a possible reverse split, and potential new analyst coverage. Quarterly cash-burn updates and Nasdaq compliance developments also merit attention. From what I see, monitoring these catalysts closely will be essential.

Exploring Tickeron’s AI Daily Buy/Sell Signals

I frequently review Tickeron’s AI Daily Buy/Sell Signals when evaluating lower-float, event-driven names. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from technical patterns and market shifts. It offers a practical way to supplement manual analysis and track evolving trends without replacing individual judgment.

Final Assessment

The $14.50 central target averages the two latest analyst calls and implies a substantial 138% advance from the recent $6.08 close. The constructive case rests on PRA-216’s multi-indication Phase 2 program, the INSPIRE platform, and the $120 million financing. The opposing view highlights dilution from the reverse merger, ongoing losses, a sub-$20 million market value, and binary clinical risk. Because every published target predates the merger and the analyst range is unusually wide, the $14.50 figure functions best as a directional reference rather than a firm prediction. Ultimately, the 2027 clinical data will carry far more weight than any prior target.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: BOLT

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


Momentum Indicator for BOLT turns negative, indicating new downward trend

BOLT saw its Momentum Indicator move below the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 98 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BOLT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 12 similar instances where the indicator moved out of overbought territory. In 10 of the 12 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Moving Average Convergence Divergence Histogram (MACD) for BOLT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BOLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

BOLT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BOLT crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.

The 50-day moving average for BOLT moved above the 200-day moving average on November 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +61.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where BOLT advanced for three days, in 156 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

BOLT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 78 of 92 cases where BOLT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. BOLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.997) is normal, around the industry mean (3.498). P/E Ratio (-0.396) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.355) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BOLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
900 Chesapeake Drive
Phone
+1 650 665-9295
Employees
23
Web
https://www.boltbio.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.